绝经前期激素替代疗法作为老年保护方法 - 调整临床指导
Jaron Rabinovici1,2, Henk-Peter Oonk3, Zhongwei Huang4,5
1Division of Obstetrics and Gynecology and Sheba Longevity Center, Sheba Medical Center, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Israel.
Aging and disease
|December 26, 2025
概括
激素替代疗法 (HRT) 可以成为绝经前期妇女的早期老年保护性干预措施,解决衰老的特征. 需要进一步的生物标志物驱动研究来优化其长寿的使用.
科学领域:
- 老年学是一门学科.
- 生殖内分泌学 生殖内分泌学
- 妇女健康 妇女健康
背景情况:
- 卵巢内分泌功能下降是女性衰老的核心原因,在生殖能力停止之前.
- 激素替代疗法 (HRT) 是一种针对衰老特征的老年保护策略.
- 尽管在临床上使用,但HRT的抗衰老潜力仍未得到充分利用.
研究的目的:
- 审查HRT作为绝经前妇女的老年保护疗法的作用.
- 强调需要基于生物标志物的研究来验证HRT的老年保护作用.
- 倡导针对绝经前期的HRT量身定制的临床指南.
主要方法:
- 关于HRT和衰老的现有文献的叙事综述.
- 专注于在更年期开始后10年内开始的HRT.
- 重点是内分泌,炎症和新陈代谢概况的绝经前期.
主要成果:
- HRT在12个衰老标志中具有机械相关性.
- 需要前性,生物标志物驱动的研究来证实老年保护疗效.
- 目前的数据表明,HRT作为早期干预的潜力.
结论:
- 对符合条件的绝经前妇女来说,HRT可以是一个有价值的老年保护性干预措施.
- 优化HRT需要特定于年龄和阶段的生物标志物来进行精确的护理.
- 制定具体的临床指导方针对于在绝经前期有效实施HRT至关重要.
相关概念视频
Menopause
3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
Drug Dosing: Geriatric Patients
206
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
206
Pharmacodynamics in Geriatric Patients: Effects of Age
174
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
174
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
205
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
205
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
209
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
209
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
178
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
178


